Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Quarterly Report & Appendix 4C: Q1 FY2027 Highlights: Clinical and regulatory development activity ? Completed enrolment of all 250 participants in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial across 78 activated US clinical...